Edition:
United Kingdom

Jaguar Health Inc (JAGX.OQ)

JAGX.OQ on NASDAQ Stock Exchange Capital Market

0.13USD
3:24pm GMT
Change (% chg)

$-0.00 (-1.53%)
Prev Close
$0.13
Open
$0.13
Day's High
$0.14
Day's Low
$0.13
Volume
46,399
Avg. Vol
379,211
52-wk High
$1.52
52-wk Low
$0.11

Select another date:

Thu, Dec 14 2017

BRIEF-Jaguar Health ‍Enters Collaboration Agreement With SEED For Equilevia​

* JAGUAR HEALTH INC - ‍ENTERED COLLABORATION AGREEMENT WITH SEED MENA BUSINESSMEN SERVICES FOR EQUILEVIA​

BRIEF-Jaguar Health enters share purchase agreement

* JAGUAR HEALTH ENTERS SHARE PURCHASE AGREEMENT FOR 2 MILLION SHARES AND COMMON STOCK PURCHASE AGREEMENT RELATING TO A 10 MILLION SHARE EQUITY LINE OFFERING WITH L2 CAPITAL, LLC

BRIEF-Jaguar Health ‍signs non-binding term sheet to issue note to Iliad Research

* Jaguar health enters non-binding agreement of terms to issue a secured convertible note to iliad research and trading, l.p. (an affiliate of chicago venture partners, l.p.), as jaguar expands commercial efforts for mytesi

BRIEF-Jaguar Health enters into letter agreement with Maxim Group LLC

* Jaguar Health - ‍on Oct 25,co entered into letter agreement with Maxim Group LLC which amends certain terms of underwriting agreement dated Sept 29​ Source text : (http://bit.ly/2y8b9cc) Further company coverage:

BRIEF-Jaguar Health files for resale or other disposition of up to 36 million shares of co

* Jaguar Health files for resale or other disposition of up to 36 million shares of co by the selling shareholders ‍​ Source text: (http://bit.ly/2gxkRxa) Further company coverage:

BRIEF-Jaguar Health prices $4.25 million public offering of common stock

* Jaguar health prices $4.25 million public offering of common stock

BRIEF-Jaguar unit Napo Pharmaceuticals files CMC supplement with FDA

* Jaguar subsidiary Napo Pharmaceuticals files CMC supplement with FDA for sample-size bottles of mytesi, Napo's FDA-approved human drug, to support upcoming national sample campaign Source text for Eikon: Further company coverage:

BRIEF-Jaguar Health says FDA indicates co's Canalevia drug qualifies as “minor use” for exercise-induced diarrhea in dogs

* FDA indicates that jaguar’s Canalevia drug product candidate qualifies as “minor use” for Exercise-Induced Diarrhea (EID) in dogs, rendering Canalevia eligible for conditional approval for this indication

BRIEF-Jaguar Health proposes public offering of common stock

* Jaguar Health announces proposed public offering of common stock

BRIEF-Jaguar Health subsidiary expands Mytesi salesforce

* Jaguar Health subsidiary Napo Pharmaceuticals expands Mytesi salesforce with hire of experienced HIV & GI drug sales reps in key U.S. markets Source text for Eikon: Further company coverage:

Select another date: